Am J Psychiatry 158:360-369, March 2001
© 2001 American Psychiatric Association
Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics?: A New Hypothesis
Shitij Kapur, M.D., Ph.D., F.R.C.P.C., and
Philip Seeman, M.D., Ph.D., F.R.S.(C.)
OBJECTIVE: Although atypical antipsychotics are becoming the treatment of choice for schizophrenia, what makes an antipsychotic "atypical" is not clear. This article provides a new hypothesis about the mechanism of action of atypical antipsychotics. METHOD: Published data regarding the molecular, animal model, neuroimaging, and clinical aspects of typical and atypical antipsychotics were reviewed to develop this hypothesis. Particular attention was paid to data regarding the role of the serotonin 5-HT2 and dopamine D4 receptors in atypicality. RESULTS: Neuroimaging data show that optimal dopamine D2 occupancy is sufficient to produce the atypical antipsychotic effect. Freedom from motor side effects results from low D2 occupancy, not from high 5-HT2 occupancy. If D2 occupancy is excessive, atypicality is lost even in the presence of high 5-HT2 occupancy. Animal data show that a rapid dissociation from the D2 receptor at a molecular level produces the atypical antipsychotic effect. In vitro data show that the single most powerful predictor of atypicality for the current generation of atypical antipsychotics is fast dissociation from the D2 receptor, not its high affinity at 5-HT2, D4, or another receptor. CONCLUSIONS: The authors propose that fast dissociation from the D2 receptor makes an antipsychotic more accommodating of physiological dopamine transmission, permitting an antipsychotic effect without motor side effects, prolactin elevation, or secondary negative symptoms. In contrast to the multireceptor hypotheses, the authors predict that the atypical antipsychotic effect can be produced by appropriate modulation of the D2 receptor alone; the blockade of other receptors is neither necessary nor sufficient.
This article has been cited by other articles:
|
|
|
|
 
J. de Leon, N. B. Sandson, and K. L. Cozza
A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part II
Psychosomatics,
July 1, 2008;
49(4):
347 - 361.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. de Leon, N. B. Sandson, and K. L. Cozza
A Preliminary Attempt to Personalize Risperidone Dosing Using Drug-Drug Interactions and Genetics: Part I
Psychosomatics,
May 1, 2008;
49(3):
258 - 270.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Walters and I. Jones
Clinical questions and uncertainty -- prolactin measurement in patients with schizophrenia and bipolar disorder
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
82 - 89.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Citrome
Current guidelines and their recommendations for prolactin monitoring in psychosis
J Psychopharmacol,
March 1, 2008;
22(2_suppl):
90 - 97.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. L. Claxton, J. J. Chen, and D. M. Swope
Drug-Induced Movement Disorders
Journal of Pharmacy Practice,
December 1, 2007;
20(6):
415 - 429.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. J. Pavlis, E. C. Kutscher, R. M. Carnahan, W. K. Kennedy, S. Van Gerpen, and E. Schlenker
Rivastigmine-induced dystonia
Am. J. Health Syst. Pharm.,
December 1, 2007;
64(23):
2468 - 2470.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Malone, R. M. Carnahan, and E. C. Kutscher
Antipsychotic Medication Use in the Elderly Patient
Journal of Pharmacy Practice,
August 1, 2007;
20(4):
318 - 326.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Rogaeva, X.-M. Ou, H. Jafar-Nejad, S. Lemonde, and P. R. Albert
Differential Repression by Freud-1/CC2D1A at a Polymorphic Site in the Dopamine-D2 Receptor Gene
J. Biol. Chem.,
July 20, 2007;
282(29):
20897 - 20905.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S.E. Keefe, J. A. Sweeney, H. Gu, R. M. Hamer, D. O. Perkins, J. P. McEvoy, and J. A. Lieberman
Effects of Olanzapine, Quetiapine, and Risperidone on Neurocognitive Function in Early Psychosis: A Randomized, Double-Blind 52-Week Comparison
Am J Psychiatry,
July 1, 2007;
164(7):
1061 - 1071.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. S. Karnik, S. V. Joshi, C. Paterno, and R. Shaw
Subtypes of Pediatric Delirium: A Treatment Algorithm
Psychosomatics,
June 1, 2007;
48(3):
253 - 257.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
References
PsychiatryOnline CME,
May 1, 2007;
2007(1):
2 - 2.
[Full Text]
|
|
|
|
|
|
|
P. Shaw, A. Sporn, N. Gogtay, G. P. Overman, D. Greenstein, P. Gochman, J. W. Tossell, M. Lenane, and J. L. Rapoport
Childhood-Onset Schizophrenia: A Double-Blind, Randomized Clozapine-Olanzapine Comparison.
Arch Gen Psychiatry,
July 1, 2006;
63(7):
721 - 730.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Remington, D. Mamo, A. Labelle, J. Reiss, C. Shammi, E. Mannaert, S. Mann, and S. Kapur
A PET Study Evaluating Dopamine D2 Receptor Occupancy for Long-Acting Injectable Risperidone
Am J Psychiatry,
March 1, 2006;
163(3):
396 - 401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. SEEMAN
An Update of Fast-Off Dopamine D2 Atypical Antipsychotics
Am J Psychiatry,
October 1, 2005;
162(10):
1984 - 1985.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. P. Dall'igna, A. B.L. Tort, D. O. Souza, and D. R. Lara
Cinnarizine has an atypical antipsychotic profile in animal models of psychosis
J Psychopharmacol,
July 1, 2005;
19(4):
342 - 346.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. M. Gardner, R. J. Baldessarini, and P. Waraich
Modern antipsychotic drugs: a critical overview
Can. Med. Assoc. J.,
June 21, 2005;
172(13):
1703 - 1711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. E. Kippin, S. Kapur, and D. van der Kooy
Dopamine Specifically Inhibits Forebrain Neural Stem Cell Proliferation, Suggesting a Novel Effect of Antipsychotic Drugs
J. Neurosci.,
June 15, 2005;
25(24):
5815 - 5823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kropp, V. Kern, K. Lange, D. Degner, G. Hajak, J. Kornhuber, E. Ruther, H. M. Emrich, U. Schneider, and S. Bleich
Oxidative Stress During Treatment With First- and Second-Generation Antipsychotics
J Neuropsychiatry Clin Neurosci,
May 1, 2005;
17(2):
227 - 231.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Bolonna and R. W. Kerwin
Partial agonism and schizophrenia
The British Journal of Psychiatry,
January 1, 2005;
186(1):
7 - 10.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Pappadopulos, J. C. MacIntyre II, M. L. Crismon, R. L. Findling, R. P. Malone, A. Derivan, N. Schooler, L. Sikich, L. Greenhill, S. B. Schur, et al.
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY) Part II
Focus,
October 1, 2004;
2(4):
608 - 624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. ROSS
Clozapine and Typical Antipsychotics
Am J Psychiatry,
October 1, 2004;
161(10):
1925 - 1926.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Tauscher, T. Hussain, O. Agid, N. P. L.G. Verhoeff, A. A. Wilson, S. Houle, G. Remington, R. B. Zipursky, and S. Kapur
Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics
Am J Psychiatry,
September 1, 2004;
161(9):
1620 - 1625.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Moresco, R. Cavallaro, C. Messa, D. Bravi, C. Gobbo, L. Galli, G. Lucignani, C. Colombo, G. Rizzo, I. Velona, et al.
Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine
J Psychopharmacol,
September 1, 2004;
18(3):
355 - 365.
[Abstract]
[PDF]
|
|
|
|
|
|
|
R. McD. YOUNG, B. R. LAWFORD, M. BARNES, S. C. BURTON, T. RITCHIE, W. K. WARD, and E. P. NOBLE
Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele
The British Journal of Psychiatry,
August 1, 2004;
185(2):
147 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Malhotra, G. M. Murphy Jr., and J. L. Kennedy
Pharmacogenetics of Psychotropic Drug Response
Am J Psychiatry,
May 1, 2004;
161(5):
780 - 796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Bressan, H. M. Jones, and L. S. Pilowsky
Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity
J Psychopharmacol,
March 1, 2004;
18(1):
124 - 127.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. P Kelleher
Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder
Evid. Based Ment. Health,
February 1, 2004;
7(1):
13 - 13.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Paquet, J. P. Soucy, E. Stip, M. Levesque, A. Elie, and M. A. Bedard
Comparison Between Olanzapine and Haloperidol on Procedural Learning and the Relationship With Striatal D2 Receptor Occupancy in Schizophrenia
J Neuropsychiatry Clin Neurosci,
February 1, 2004;
16(1):
47 - 56.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. D. Jibson, I. D. Glick, and R. Tandon
Schizophrenia and Other Psychotic Disorders
Focus,
January 1, 2004;
2(1):
17 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Grunder, A. Carlsson, and D. F. Wong
Mechanism of New Antipsychotic Medications: Occupancy Is Not Just Antagonism
Arch Gen Psychiatry,
October 1, 2003;
60(10):
974 - 977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Bressan, K. Erlandsson, H. M. Jones, R. Mulligan, R. J. Flanagan, P. J. Ell, and L. S. Pilowsky
Is Regionally Selective D2/D3 Dopamine Occupancy Sufficient for Atypical Antipsychotic Effect? An In Vivo Quantitative [123I]Epidepride SPET Study of Amisulpride-Treated Patients
Am J Psychiatry,
August 1, 2003;
160(8):
1413 - 1420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Takahashi, H. Higuchi, M. Kamata, S. Naitoh, K. Yoshida, T. Shimizu, and T. Sugita
Effectiveness of Switching to Quetiapine for Neuroleptic-Induced Amenorrhea
J Neuropsychiatry Clin Neurosci,
August 1, 2003;
15(3):
375 - 377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. G. Potkin, A. R. Saha, M. J. Kujawa, W. H. Carson, M. Ali, E. Stock, J. Stringfellow, G. Ingenito, and S. R. Marder
Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone vs Placebo in Patients With Schizophrenia and Schizoaffective Disorder
Arch Gen Psychiatry,
July 1, 2003;
60(7):
681 - 690.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M L. Crismon, A. DeLeon, and A. L Miller
Aripiprazole: Does Partial Dopaminergic Agonism Translate into Clinical Benefits?
Ann. Pharmacother.,
May 1, 2003;
37(5):
738 - 740.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Scahill, J.F. Leckman, R.T. Schultz, L. Katsovich, and B.S. Peterson
A placebo-controlled trial of risperidone in Tourette syndrome
Neurology,
April 8, 2003;
60(7):
1130 - 1135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. WIECK and P. M. HADDAD
Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: Selective literature review
The British Journal of Psychiatry,
March 1, 2003;
182(3):
199 - 204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F.-M. Zhou, C. Wilson, and J. A. Dani
Muscarinic and Nicotinic Cholinergic Mechanisms in the Mesostriatal Dopamine Systems
Neuroscientist,
February 1, 2003;
9(1):
23 - 36.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. de Haan, M. van Bruggen, J. Lavalaye, J. Booij, P. M.A.J. Dingemans, and D. Linszen
Subjective Experience and D2 Receptor Occupancy in Patients With Recent-Onset Schizophrenia Treated With Low-Dose Olanzapine or Haloperidol: A Randomized, Double-Blind Study
Am J Psychiatry,
February 1, 2003;
160(2):
303 - 309.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur
Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia
Am J Psychiatry,
January 1, 2003;
160(1):
13 - 23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Tofler
Olanzapine and Neuroleptic Malignant Syndrome
Psychosomatics,
December 1, 2002;
43(6):
505 - 506.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. BILDER, J. VOLAVKA, L. CITROME, P. CZOBOR, M. HOPTMAN, M. CHAKOS, J. P. McEVOY, T. B. COOPER, and J. A. LIEBERMAN
Dr. Bilder and Colleagues Reply
Am J Psychiatry,
December 1, 2002;
159(12):
2118 - 2119.
[Full Text]
|
|
|
|
|
|
|
T. W. Weickert, A. Terrazas, L. B. Bigelow, J. D. Malley, T. Hyde, M. F. Egan, D. R. Weinberger, and T. E. Goldberg
Habit and Skill Learning in Schizophrenia: Evidence of Normal Striatal Processing With Abnormal Cortical Input
Learn. Mem.,
November 1, 2002;
9(6):
430 - 442.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. JONES and L. S. PILOWSKY
Dopamine and antipsychotic drug action revisited
The British Journal of Psychiatry,
October 1, 2002;
181(4):
271 - 275.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H.-Y. Lane, Y.-C. Chang, C.-C. Chiu, M.-L. Chen, M.-H. Hsieh, and W.-H. Chang
Association of Risperidone Treatment Response With a Polymorphism in the 5-HT2A Receptor Gene
Am J Psychiatry,
September 1, 2002;
159(9):
1593 - 1595.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur, X. Langlois, P. Vinken, A. A. H. P. Megens, R. De Coster, and J. S. Andrews
The Differential Effects of Atypical Antipsychotics on Prolactin Elevation Are Explained by Their Differential Blood-Brain Disposition: A Pharmacological Analysis in Rats
J. Pharmacol. Exp. Ther.,
September 1, 2002;
302(3):
1129 - 1134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Adams
List of atypical drugs?
Psychiatr. Bull.,
September 1, 2002;
26(9):
356 - 356.
[Full Text]
|
|
|
|
|
|
|
J. T. McCracken, J. McGough, B. Shah, P. Cronin, D. Hong, M. G. Aman, L. E. Arnold, R. Lindsay, P. Nash, J. Hollway, et al.
Risperidone in Children with Autism and Serious Behavioral Problems
N. Engl. J. Med.,
August 1, 2002;
347(5):
314 - 321.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. C. Goff
A 23-Year-Old Man With Schizophrenia
JAMA,
June 26, 2002;
287(24):
3249 - 3257.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kapur and P. Seeman
Atypical antipsychotics, cortical D2 receptors and sensitivity to endogenous dopamine
The British Journal of Psychiatry,
May 1, 2002;
180
(5):
465 - 466.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Lewis
Atypical Antipsychotic Medications and the Treatment of Schizophrenia
Am J Psychiatry,
February 1, 2002;
159(2):
177 - 179.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Y. MELTZER
Action of Atypical Antipsychotics
Am J Psychiatry,
January 1, 2002;
159(1):
153 - 154.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. F. Wong
In Vivo Imaging of D2 Dopamine Receptors in Schizophrenia: The Ups and Downs of Neuroimaging Research
Arch Gen Psychiatry,
January 1, 2002;
59(1):
31 - 34.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. McIntosh, S. M. Lawri, and D. Taylor
Low dose typical antipsychotics -- a brief evaluationAuthor's reply
Psychiatr. Bull.,
July 1, 2001;
25(7):
276 - 276.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric |
